Bristol Myers Squibb’s cell therapy gets USFDA nod for relapsed or refractory follicular lymphoma Read more
US FDA approves Bristol Myers Squibb’s CAR-T cell therapy Breyanzi for relapsed large B-cell lymphoma after one prior therapy Read more